<DOC>
	<DOC>NCT02982707</DOC>
	<brief_summary>A single oral dose of BMS-986177administered to subjects of mild hepatic impairment, moderate hepatic impairment and healthy matched subjects to evaluate pharmacokinetics, safety, and tolerability in these subjects</brief_summary>
	<brief_title>Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>BMI of 20.0 to 38.0 kg/m2, inclusive Hepatic subjects classified as ChildPugh mild (Class A) or ChildPugh moderate (Class B) who have had no significant change to disease status in past 6 months and are on stable treatment regimen Healthy subjects must not have clinically significant deviations from normal in medical history, physical exam, ECGs, vital signs or clinical lab values Women must be not of child bearing potential and males who are sexually active with a woman of child bearing potential must agreed to use acceptable contraception for 92 days following dosing Evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation Use of corticosteroids, nonsteroidal antiinflammatory compounds, aspirin or other antiplatelet agents or anticoagulants within 2 weeks of dosing Healthy subjects must not have used tobacco or have a history of drug or alcohol abuse within the last 6 months Subjects must not have a current or recent (within 3 months) GI disease that increases participant risk of GI bleeding or interferes with absorption of the study drug Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>